CN112702998A - 作为lpa拮抗剂的环庚酸 - Google Patents
作为lpa拮抗剂的环庚酸 Download PDFInfo
- Publication number
- CN112702998A CN112702998A CN201980060422.9A CN201980060422A CN112702998A CN 112702998 A CN112702998 A CN 112702998A CN 201980060422 A CN201980060422 A CN 201980060422A CN 112702998 A CN112702998 A CN 112702998A
- Authority
- CN
- China
- Prior art keywords
- independently
- lpa
- alkyl
- cancer
- fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732595P | 2018-09-18 | 2018-09-18 | |
| US62/732,595 | 2018-09-18 | ||
| PCT/US2019/051275 WO2020060916A1 (en) | 2018-09-18 | 2019-09-16 | Cycloheptyl acids as lpa antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112702998A true CN112702998A (zh) | 2021-04-23 |
Family
ID=68073224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980060422.9A Pending CN112702998A (zh) | 2018-09-18 | 2019-09-16 | 作为lpa拮抗剂的环庚酸 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220041572A1 (enExample) |
| EP (1) | EP3852747B1 (enExample) |
| JP (1) | JP7429224B2 (enExample) |
| KR (1) | KR102800284B1 (enExample) |
| CN (1) | CN112702998A (enExample) |
| ES (1) | ES2948793T3 (enExample) |
| WO (1) | WO2020060916A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117295724A (zh) * | 2021-05-13 | 2023-12-26 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| WO2026061483A1 (zh) * | 2024-09-19 | 2026-03-26 | 西藏海思科制药有限公司 | 一种lpar1拮抗剂及其用途 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7412424B2 (ja) * | 2018-09-18 | 2024-01-12 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのオキサビシクロ酸 |
| ES2946657T3 (es) * | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
| CN114728168B (zh) | 2019-11-15 | 2024-04-09 | 吉利德科学公司 | 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途 |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| US11702407B2 (en) | 2020-06-03 | 2023-07-18 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| AU2022273631B2 (en) | 2021-05-11 | 2025-04-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| TW202342017A (zh) | 2022-02-25 | 2023-11-01 | 美商洛子峰生物有限公司 | 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物 |
| IL326963A (en) | 2023-09-08 | 2026-05-01 | Haisco Pharmaceutical Group Co Ltd | LPAR1 antagonist and its use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1364659B1 (en) | 2001-02-08 | 2009-11-11 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| TW201120016A (en) * | 2009-12-08 | 2011-06-16 | Abbott Lab | Novel oxadiazole compounds |
| US9527807B2 (en) | 2011-04-05 | 2016-12-27 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| SG11201407220YA (en) | 2012-06-20 | 2014-12-30 | Hoffmann La Roche | N-alkyltriazole compounds as lpar antagonists |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| JP7412424B2 (ja) | 2018-09-18 | 2024-01-12 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのオキサビシクロ酸 |
| ES2946657T3 (es) | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
-
2019
- 2019-09-16 KR KR1020217011086A patent/KR102800284B1/ko active Active
- 2019-09-16 JP JP2021515027A patent/JP7429224B2/ja active Active
- 2019-09-16 EP EP19779300.3A patent/EP3852747B1/en active Active
- 2019-09-16 US US17/276,178 patent/US20220041572A1/en not_active Abandoned
- 2019-09-16 ES ES19779300T patent/ES2948793T3/es active Active
- 2019-09-16 CN CN201980060422.9A patent/CN112702998A/zh active Pending
- 2019-09-16 WO PCT/US2019/051275 patent/WO2020060916A1/en not_active Ceased
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117295724A (zh) * | 2021-05-13 | 2023-12-26 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| CN117295724B (zh) * | 2021-05-13 | 2026-04-17 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| WO2026061483A1 (zh) * | 2024-09-19 | 2026-03-26 | 西藏海思科制药有限公司 | 一种lpar1拮抗剂及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022500469A (ja) | 2022-01-04 |
| WO2020060916A1 (en) | 2020-03-26 |
| ES2948793T3 (es) | 2023-09-19 |
| KR102800284B1 (ko) | 2025-04-23 |
| EP3852747A1 (en) | 2021-07-28 |
| US20220041572A1 (en) | 2022-02-10 |
| KR20210060547A (ko) | 2021-05-26 |
| JP7429224B2 (ja) | 2024-02-07 |
| EP3852747B1 (en) | 2023-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11261174B2 (en) | Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists | |
| US11384067B2 (en) | Pyrazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | |
| US11319309B2 (en) | Cyclohexyl acid isoxazole azines as LPA antagonists | |
| EP3728242B1 (en) | Cyclohexyl acid isoxazole azoles as lpa antagonists | |
| EP3852746B1 (en) | Cyclopentyl acids as lpa antagonists | |
| CN112041316B (zh) | 作为lpa拮抗剂的异噁唑o-连接的氨基甲酰基环己基酸 | |
| EP3986553B1 (en) | Cyclobutyl carboxylic acids as lpa antagonists | |
| CN112055710B (zh) | 作为lpa拮抗剂的环己基酸吡唑吖嗪 | |
| CN112041029B (zh) | 作为lpa拮抗剂的环己基酸吡唑唑类 | |
| KR102800284B1 (ko) | Lpa 길항제로서의 시클로헵틸 산 | |
| CN112189010A (zh) | 作为lpa拮抗剂的三唑n-连接的氨基甲酰基环己基酸 | |
| CN114599648A (zh) | 作为lpa拮抗剂的三唑羧酸 | |
| CN113366000A (zh) | 作为lpa拮抗剂的氧杂双环酸 | |
| CN114599640A (zh) | 作为lpa拮抗剂的异噁唑羧酸 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |